Spasticity may be reduced in RRMS patients - Copaxone

A board to discuss the Multiple Sclerosis modifying drug Copaxone

Spasticity may be reduced in RRMS patients - Copaxone

Postby MSUK » Thu Apr 26, 2012 11:32 pm

Preliminary data suggest spasticity may be reduced in RRMS patients who transitioned to Copaxone


Teva Pharmaceutical Industries Ltd. announced interim data from a prospective, open label survey study evaluating spasticity in patients with relapsing-remitting multiple sclerosis (RRMS) who transitioned to Copaxone® (glatiramer acetate injection) from interferon-beta treatment. These data were presented today at the 64th Annual Meeting of the American Academy of Neurology (AAN) in New Orleans, Louisiana.

Interim results for the first 52 of 110 participants revealed a significant reduction in muscle stiffness, pain and discomfort, as well as the effect of spasticity on the ability to walk, body movements and activities of daily living (ADLs). Improvement was also found in reduction of total spasticity scores during the six month period.... Read More - ... ageid/1767
User avatar
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 3:00 pm


Return to Copaxone


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service